In Down's Syndrome, Amyloid Vaccine Opens Door to Trials
ACI-24 prompted an immune response without serious side effects, according to AC Immune. Researchers are gearing up for other treatment trials in DS.
17 RESULTS
Sort By:
Go to another page:
ACI-24 prompted an immune response without serious side effects, according to AC Immune. Researchers are gearing up for other treatment trials in DS.
Longitudinal studies in DS have pegged biomarkers and cognitive measures as potential clinical trial readouts. Hundreds of adults are anticipated to join trial-ready cohorts this year.
Go to another page: